Abstract
Purpose
We aimed to compare expression levels of miRNA-21, -103, -129, -150 in primary tumour tissues and its omental metastases from patients operated for advanced ovarian serous cancer. Expression levels of selected miRNAs were correlated with clinicopathological features, including chemosensitivity and survival.
Methods
We performed total RNA extraction from archival formalin-fixed paraffin-embedded tissue samples of primary serous ovarian cancer and omental metastases. The study included 48 patients with advanced ovarian cancer. The reference group consisted of 48 normal ovarian tissue samples. We performed cDNA synthesis, real time polymerase chain reaction and assessed relative expression of selected miRNAs.
Results
Samples derived from serous ovarian cancer were characterized by higher expression levels of miRNA-150 in comparison to omental metastases (p = 0.045). Furthermore, we observed that shorter progression free-survival was associated with lower levels of miRNA-150 in metastatic tissues. We did not find similar relationships for other miRNAs.
Conclusions
MiRNA-150 may potentially serve as a prognostic factor in advanced ovarian cancer. However, further studies are required to clearly confirm such hypothesis.
Similar content being viewed by others
References
Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T (2001) Identification of novel genes coding for small expressed RNAs. Science 294(5543):853–858
Bartel DP (2004) Micrornas: genomics, biogenesis, mechanism, and function. Cell 116:281–297
Kang HY (2013) MicroRNA-21 regulates stemness in cancer cells. Stem Cell Res Ther 4:110
Conev NV, Donev IS, Konsoulova-Kirova AA, Chervenkov TG, Kashlov JK, Ivanov KD (2015) Serum expression levels of miR-17, miR-21, and miR-92 as potential biomarkers for recurrence after adjuvant chemotherapy in colon cancer patients. Biosci Trends 9:393–401. https://doi.org/10.5582/bst.2015.01170
Chen H, Liu H, Zou H, Chen R, Dou Y, Sheng S et al (2016) Evaluation of plasma miR-21 and miR-152 as diagnostic biomarkers for common types of human cancers. J Cancer 7:490–499. https://doi.org/10.7150/jca.12351
Kuang Y, Nie YJ (2016) Exploration of the regulatory effect of miR-21 on breast cancer cell line proliferation and invasion as well as the downstream target genes. Asian Pac J Trop Med 9:470–473. https://doi.org/10.1016/j.apjtm.2016.03.025
Wei X, Wang W, Wang L, Zhang Y, Zhang X, Chen M et al (2016) MicroRNA-21 induces 5-fluorouracil resistance in human pancreatic cancer cells by regulating PTEN and PDCD4. Cancer Med 5:693–702. https://doi.org/10.1002/cam4.626
Chen S, Sun KX, Liu BL, Zong ZH, Zhao Y (2016) The role of glycogen synthase kinase-3β (GSK-3β) in endometrial carcinoma: a carcinogenesis, progression, prognosis, and target therapy marker. Oncotarget 7:27538–27551. https://doi.org/10.18632/oncotarget.8485
Yang Y, Huang JQ, Zhang X, Shen LF (2015) MiR-129-2 functions as a tumor suppressor in glioma cells by targeting HMGB1 and is down-regulated by DNA methylation. Mol Cell Biochem 404:229–239
Li M, Tian L, Wang L, Yao H, Zhang J, Lu J, Sun Y et al (2013) Down-regulation of miR-129-5p inhibits growth and induces apoptosis in laryngeal squamous cell carcinoma by targeting APC. PLoS One 8(10):e77829. https://doi.org/10.1371/journal.pone.0077829
Xu S, Yi XM, Zhou WQ, Cheng W, Ge JP, Zhang ZY (2015) Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer. Int J Clin Exp Pathol 8:14335–14344
Yu D, Zhou H, Xun Q, Xu X, Ling J, Hu Y (2012) microRNA-103 regulates the growth and invasion of endometrial cancer cells through the downregulation of tissue inhibitor of metalloproteinase 3. Oncol Lett. 3:1221–1226
Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P et al (2007) Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 25:387–392
Geng L, Sun B, Gao B, Wang Z, Quan C, Wei F, Fang XD (2014) MicroRNA-103 promotes colorectal cancer by targeting tumor suppressor DICER and PTEN. Int J Mol Sci 15:8458–8472. https://doi.org/10.3390/ijms15058458
Chen HY, Lin YM, Chung HC, Lang YD, Lin CJ, Huang J et al (2012) miR-103/107 promote metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4. Cancer Res 72:3631–3641. https://doi.org/10.1158/0008-5472.CAN-12-0667
Srivastava SK, Bhardwaj A, Singh S, Arora S, Wang B, Grizzle WE, Singh AP (2011) MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells. Carcinogenesis 32:1832–1839. https://doi.org/10.1093/carcin/bgr223
Wu Q, Jin H, Yang Z, Luo G, Lu Y, Li K et al (2010) MiR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2. Biochem Biophys Res Commun 392:340–345. https://doi.org/10.1016/j.bbrc.2009.12.182
Zhang N, Wei X, Xu L (2013) miR-150 promotes the proliferation of lung cancer cells by targeting P53. FEBS Lett 587:2346–2351. https://doi.org/10.1016/j.febslet.2013.05.059
Polytarchou C, Iliopoulos D, Hatziapostolou M, Kottakis F, Maroulakou I, Struhl K, Tsichlis PN (2011) Akt2 regulates all Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation. Cancer Res 71:4720–4731. https://doi.org/10.1158/0008-5472.CAN-11-0365
Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC et al (1992) AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 89:9267–9271
Echevarría-Vargas IM, Valiyeva F, Vivas-Mejía PE (2014) Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway. PLoS One 9(5):e97094. https://doi.org/10.1371/journal.pone.0097094
Xie Z, Cao L, Zhang J (2013) miR-21 modulates paclitaxel sensitivity and hypoxia-inducible factor-1α expression in human ovarian cancer cells. Oncol Lett 6:795–800
Chan JK, Blansit K, Kiet T, Sherman A, Wong G, Earle C, Bourguignon LY (2014) The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer. Gynecol Oncol 132:739–744. https://doi.org/10.1016/j.ygyno.2014.01.034
Chen Y, Chen Q, Liu Q, Gao F (2016) Human epididymis protein 4 expression positively correlated with miR-21 and served as a prognostic indicator in ovarian cancer. Tumour Biol 37:8359–8365. https://doi.org/10.1007/s13277-015-4672-8
Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P et al (2007) MicroRNA signatures in human ovarian cancer. Cancer Res 67:8699–8707
Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH et al (2008) MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 14:2690–2695
Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih IeM, Zhang Y, Wood W 3rd, Becker KG, Morin PJ (2008) MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 3(6):e2436. https://doi.org/10.1371/journal.pone.0002436
Ho ES, Lai CR, Hsieh YT, Chen JT, Lin AJ, Hung MH, Liu FS (2001) p53 mutation is infrequent in clear cell carcinoma of the ovary. Gynecol Oncol 80:189–193
Wiegand et al (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363:1532–1543
Bell D, Berchuck A, Birrer M, Chien J, Cramer D, Dao F et al (2011) Cancer genome atlas research network. Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609–615. https://doi.org/10.1038/nature10166
Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T et al (2015) A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ. Oncotarget 6(11):8676–8686
Kan CW, Hahn MA, Gard GB, Maidens J, Huh JY, Marsh DJ, Howell VM (2012) Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer 12:627. https://doi.org/10.1186/1471-2407-12-627
Vang S, Wu HT, Fischer A, Miller DH, MacLaughlan S, Douglass E et al (2013) Identification of ovarian cancer metastatic miRNAs. PLoS One 8(3):e58226. https://doi.org/10.1371/journal.pone.0058226
Jin M, Yang Z, Ye W, Xu H, Hua X (2014) MicroRNA-150 predicts a favorable prognosis in patients with epithelial ovarian cancer, and inhibits cell invasion and metastasis by suppressing transcriptional repressor ZEB1. PLoS One 9(8):e103965. https://doi.org/10.1371/journal.pone.0103965
Wang DT, Ma ZL, Li YL, Wang YQ, Zhao BT, Wei JL et al (2013) miR-150, p53 protein and relevant miRNAs consist of a regulatory network in NSCLC tumorigenesis. Oncol Rep 30(1):492–498. https://doi.org/10.3892/or.2013.2453
Funding
The study was financed from Polish Mother’s Memorial Hospital Research Institute internal Grant no. 2014/VII/25-GW.
Author information
Authors and Affiliations
Contributions
All authors read and approved the final manuscript. MW—corresponding author who designed the study, wrote the paper and analysed data. EZ—selection of patients and tissue samples, data analysis. JD—clinical data collection, analysis of data. MD—histopathological assessment of samples. BS—PCR quantification. MN—data collection and interpretation. JM—data collection. DO—data collection. JRW—designed the study, supervised and edited the manuscript, final approval of the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
Ethical approval was obtained from Polish Mother’s Memorial Hospital Research Institute Ethics Committee.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Human/animal rights statement
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Rights and permissions
About this article
Cite this article
Wilczyński, M., Żytko, E., Danielska, J. et al. Clinical significance of miRNA-21, -103, -129, -150 in serous ovarian cancer. Arch Gynecol Obstet 297, 741–748 (2018). https://doi.org/10.1007/s00404-018-4660-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-018-4660-5